Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Cash from Investing Activities (2024 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Cash from Investing Activities for 6 consecutive years, with -$3.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities changed N/A to -$3.0 million in Q4 2025 year-over-year; TTM through Oct 2025 was -$3.0 million, a 75.0% increase, with the full-year FY2025 number at -$7.0 million, down 40.0% from a year prior.
  • Cash from Investing Activities was -$3.0 million for Q4 2025 at PharmaCyte Biotech, up from -$7.0 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of -$3.0 million in Q4 2025 to a low of -$7.0 million in Q3 2024.